Concise synthesis and structure-activity relationships of combretastatin A-4 analogues, 1-aroylindoles and 3-aroylindoles, as novel classes of potent antitubulin agents

Journal of Medicinal Chemistry

Volumn 47, Issue 17, 2004, Pages 4247-4257

  Liou, Jing Ping ^a   Chang, Yi Ling ^b   Kuo, Fu Ming ^a   Chang, Chun Wei ^a   Tseng, Huan Yi ^b   Wang, Chiung Chiu ^a   Yang, Yung Ning ^b   Chang, Jang Yang ^c   Lee, Shiow Ju ^b   Hsieh, Hsing Pang ^a  

^a Medicinal Synthetic Laboratory   (Taiwan)

^b Div of Biotech/Pharmaceut Res   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 METHOXY 3 (3',4',5' TRIMETHOXYBENZOYL)INDOLE; 6 ETHOXY 3 (3',4',5' TRIMETHOXYBENZOYL)INDOLE; 6 METHOXY 3 (3',4',5' TRIMETHOXYBENZOYL)INDOLE; 6 METHOXY 3 (3',4',5' TRIMETHOXYBENZYL)INDOLE; 6 METHOXY 3 (3',5' DIMETHOXYBENZOYL)INDOLE; ANTINEOPLASTIC AGENT; BENZOPHENONE DERIVATIVE; CARBONYL DERIVATIVE; COMBRETASTATIN A4; COMBRETASTATIN A4 PHOSPHATE; INDOLE DERIVATIVE; METHYL GROUP; PROTEIN INHIBITOR; TUBULIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; POLYMERIZATION; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; BIOPOLYMERS; CELL LINE, TUMOR; CRYSTALLOGRAPHY, X-RAY; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; MOLECULAR STRUCTURE; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN; TUBULIN MODULATORS;

EID: 3843136376     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049802l     Document Type: Article

References (21)

1. Jordan, A.; Hadfield, J. A.; Lawrence, N. J.; McGown, A. T. Tubulin as a Target for Anticancer Drugs: Agents Which Interact with the Mitotic Spindle. Med. Res. Rev. 1998, 18, 259-296.
2. Hamel, E. Antimitotic Natural Products and Their Interactions with Tubulin. Med. Res. Rev. 1996, 16, 207-231.
3. Thorpe, P. E.; Chaplin, D. J.; Blakey, D. C. The First International Conference on Vascular Targeting: Meeting Overview. Cancer Res. 2003, 63, 1144-1147.
4. Lin, C. M.; Singh, S. B.; Chu, P. S.; Dempcy, R. O.; Schmidt, J. M.; Pettit, G. R.; Hamel, E. Interactions of Tubulin with Potent Natural and Synthetic Analogues of the Antimitotic Agent Combretastatin: A Structure-Activity Study. Mol Pharmacol 1988, 34, 200-208.
5. (a) Tozer, G. M.; Kanthou, C.; Parkins, C. S.; Hill, S. A. The Biology of the Combretastatins as Tumour Vascular Targeting Agents. Int. J. Exp. Pathol. 2002, 83, 21-38.
6. (b) Griggs, J.; Metcalfe, J. C.; Hesketh, R. Targeting Tumour Vasculature: The Development of Combretastatin A4. Lancet Oncol. 2001, 2, 82-87.
7. (a) Nam, N. H. Combretastatin A-4 Analogues as Antimitotic Antitumor Agents. Curr. Med. Chem. 2003, 10, 1697-1722.
8. (b) Li, Q.; Sham, H. L. Discovery and Development of Antimitotic Agents That Inhibit Tubulin Polymerisation for the Treatment of Cancer. Exp. Opin. Ther. Patents 2002, 12, 1663-1702.
9. (c) Cirla, A.; Mann, J. Combretastatins: From Natural Products to Drug Discovery. Nat. Prod. Rep. 2003, 20, 558-564.
10. (d) Tahir, S. K.; Nukkala, M. A.; Zielinski Mozny, N. A.; Credo, R. B.; Warner, R. B.; Li, Q.; Woods, K. W.; Claiborne, A.; Gwaltney, S. L., II; Frost, D. J.; Sham, H. L.; Rosenberg, S. H.; Ng, S. C. Biological Activity of A-289099: an Orally Active Tubulin-binding Indolyloxazoline Derivati8ve. Mol. Cancer Ther. 2003, 2, 227-233.
11. (e) Bailly, C.; Bal, C.; Barbier, P.; Combes, S.; Finet, J. P.; Hildebrand, M. P.; Peyrot, V.; Wattez, N. Synthesis and Biological Evaluation of 4-Arylcoumarin Analogues of Combretastatins. J. Med. Chem. 2003, 46, 5437-5444.
12. (a) Pettit, G. R.; Toki, B.; Herald, D. L.; Verdier-Pinard, P.; Boyd, M. R.; Hamel, E.; Pettit, R. K. Antineoplastic Agents. 379. Synthesis of Phenstatin Phosphate. J. Med. Chem. 1998, 41, 1688-1695.
13. (b) Liou, J. P.; Chang, C. W.; Song, J. S.; Yang, Y. N.; Yeh, C. F.; Tseng, H. Y.; Lo, Y. K.; Chang, Y. L.; Chang, C. M.; Hsieh, H. P. Synthesis and Structure-Activity Relationship of 2-Aminobenzophenone Derivatives as Antimitotic Agents. J. Med. Chem. 2002, 45, 2556-2562.
14. (c) Hsieh, H. P.; Liou, J. P.; Lin, Y. T.; Mahindroo, N.; Chang, J. Y.; Yang, Y. N.; Chern, S. S.; Tan, U. K.; Chang, C. W.; Chen, T. W.; Lin, C. H.; Chang, Y. Y.; Wang, C. C. Structure-Activity and Crystallographic Analysis of Benzophenone Derivatives - the Potential Anticancer Agents. Bioorg. Med. Chem. Lett. 2003, 13, 101-105.
15. Liou, J. P.; Chang, J. Y.; Chang, C. W.; Chang, C. Y.; Mahindroo, N.; Kuo, F. M.; Hsieh, H. P. Synthesis and Structure-Activity Relationships of 3-Aminobenzophenones as Antimitotic Agents. J. Med. Chem. 2004, 47, 2897-2905.
16. Yang, C. X.; Patel, H. H.; Ku, Y. Y.; Shah, R.; Sawick, D. The Use of Lewis Acid in the Reaction of Zinc Salts of Indoles and Acyl Chloride. Synth. Commun. 1997, 27, 2125-2132.
17. Pettit, G. R.; Singh, S. B.; Niven, M. L.; Hamel, E.; Schmidt, J. M. Isolation, Structure, and Synthesis of Combretastatins A-1 and B-1, Potent New Inhibitors of Microtubule Assembly, Derived from Combretum Caffrum. J. Nat. Prod. 1987, 50, 119-131.
18. Cushman, M.; Nagarathnam, D.; Gopal, D.; Lin, C. M.; Hamel, E. Synthesis and Evaluation of Analogues of (Z)-1-(4-Methoxyphenyl)-2-(3,4,5- trimethoxyphenyl)ethane as Potential Cytotoxic and Antimitotic Agents. J. Med. Chem. 1992, 35, 2293-2306.
19. Kuo, C. C.; Hsieh, H. P.; Pan, W. Y.; Chen, C. P.; Liou, J. P.; Lee, S. J.; Chang, Y. L.; Chen, L. T.; Chen, C. T.; Chang, J. Y. BPR0L075, a Novel Synthetic Indole Compound with Antimitotic Activity in Human Cancer Cells, Exerts Effective Antitumoral Activity in Vivo. Cancer Res. 2004, 64, 4621-4628.
20. Bollag, D. M.; McQueney, P. A.; Zhu, J.; Hensens, O.; Koupal, L.; Liesch, J.; Goetz, M.; Lazarides, E.; Woods, C. M. Epothilones, a New Class of Microtubule-stabilizing Agents with a Taxol-like Mechanism of Action. Cancer Res. 1995, 55, 2325-2333.
21. Chang, J. Y.; Hsieh, H. P.; Pan, W. Y.; Liou, J. P.; Bey, S. J.; Chen, L. T.; Song, J. S. Dual Inhibition of Topoisomerase I and Tubulin Polymerization by BPR0Y007, a Novel Cytotoxic Agent. Biochem. Pharmacol. 2003, 65, 2009-2019.